Sareum Holdings plc is a United Kingdom-based specialist drug development company. The Company is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused advancing the dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the cytokine storm immune system overreaction to Covid-19 and other viral infections (SDC-1801) and cancer immunotherapy (SDC-1802). The Company has interest in SRA737, which is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and deoxyribonucleic (DNA) damage repair mechanisms. In addition, the Company manufactures SDC-1801 drug substance and oral capsule formulation under good manufacturing practice (GMP) conditions is on track to enable the Phase Ia trial.